Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 34
2005 47
2006 65
2007 85
2008 26
2009 59
2010 79
2011 109
2012 82
2013 87
2014 18
2015 2
2016 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

617 results
Results by year
Filters applied: . Clear all
Page 1
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M. Sgroi DC, et al. Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12. Lancet Oncol. 2013. PMID: 24035531 Free PMC article. Clinical Trial.
FINDINGS: Suitable tissue was available from 665 patients with oestrogen-receptor-positive, N0 breast cancer for BCI analysis. ...FUNDING: Avon Foundation, National Institutes of Health, Breast Cancer Foundation, US Department of Defense Breast Cancer Researc …
FINDINGS: Suitable tissue was available from 665 patients with oestrogen-receptor-positive, N0 breast cancer for BCI analysis. ...FUN …
Cost of managing women presenting with stage IV breast cancer in the United Kingdom.
Remák E, Brazil L. Remák E, et al. Br J Cancer. 2004 Jul 5;91(1):77-83. doi: 10.1038/sj.bjc.6601890. Br J Cancer. 2004. PMID: 15188011 Free PMC article.
This study estimated lifetime cost of treatment for patients in the United Kingdom (UK) presenting with stage IV breast cancer. ...Only five cancer registries in the UK document the proportion of breast cancer patients diagnosed with stage IV disease. Their data was …
This study estimated lifetime cost of treatment for patients in the United Kingdom (UK) presenting with stage IV breast cancer. ...On …
Sex hormones and breast cancer risk and prognosis.
Folkerd E, Dowsett M. Folkerd E, et al. Breast. 2013 Aug;22 Suppl 2:S38-43. doi: 10.1016/j.breast.2013.07.007. Breast. 2013. PMID: 24074790 Free article. Review.
The study of large prospective collections of plasma samples from women prior to the development of breast cancer has firmly established certain sex steroids as being significantly associated with risk. ...Plasma androgen levels also show a relationship with breast
The study of large prospective collections of plasma samples from women prior to the development of breast cancer has firmly establis …
Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dörk T, Van't Veer LJ; Breast Cancer Association Consortium. Schmidt MK, et al. Cancer Res. 2007 Oct 1;67(19):9584-90. doi: 10.1158/0008-5472.CAN-07-0738. Cancer Res. 2007. PMID: 17909070 Free article.
Association studies in large series of breast cancer patients can be used to identify single-nucleotide polymorphisms (SNP) contributing to breast cancer susceptibility. ...We therefore investigated the effect of TP53 R72P and MDM2 SNP309 on breast cancer ris …
Association studies in large series of breast cancer patients can be used to identify single-nucleotide polymorphisms (SNP) contribut …
Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J. Johnson N, et al. Lancet. 2005 Oct 29-Nov 4;366(9496):1554-7. doi: 10.1016/S0140-6736(05)67627-1. Lancet. 2005. PMID: 16257342 Review.
Our aim was to measure the risk of breast cancer in relatives of women with bilateral breast cancer who were carriers of this allele. ...Bilateral breast cancer cases and their families are likely to provide an efficient basis for identification of additional …
Our aim was to measure the risk of breast cancer in relatives of women with bilateral breast cancer who were carriers of this …
The anatomy of fluid-yielding ducts in breast cancer.
Twelves D, Nerurkar A, Osin P, Ward A, Isacke CM, Gui GP. Twelves D, et al. Breast Cancer Res Treat. 2012 Apr;132(2):555-64. doi: 10.1007/s10549-011-1623-y. Epub 2011 Jun 15. Breast Cancer Res Treat. 2012. PMID: 21674221
The aim of this study was to determine how often duct lavage fluid drains the breast cancer-affected segment. 58 patients undergoing mastectomy for breast cancer were recruited among which 47 had at least one fluid-yielding duct. ...Further quantitative study of …
The aim of this study was to determine how often duct lavage fluid drains the breast cancer-affected segment. 58 patients undergoing …
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators. Cuzick J, et al. Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12. Lancet. 2014. PMID: 24333009 Free article. Clinical Trial.
BACKGROUND: Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. ...The primary endpoint was histologically confirmed breast cancer (invasive cancers or non-invasive ductal carcinoma …
BACKGROUND: Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmen …
Genomic profiling of histological special types of breast cancer.
Horlings HM, Weigelt B, Anderson EM, Lambros MB, Mackay A, Natrajan R, Ng CK, Geyer FC, van de Vijver MJ, Reis-Filho JS. Horlings HM, et al. Breast Cancer Res Treat. 2013 Nov;142(2):257-69. doi: 10.1007/s10549-013-2740-6. Epub 2013 Oct 27. Breast Cancer Res Treat. 2013. PMID: 24162157
Histological special types of breast cancer have distinctive morphological features and account for up to 25 % of all invasive breast cancers. ...We characterized 59 breast cancers of ten histological special types using array-based comparative genomic hybrid …
Histological special types of breast cancer have distinctive morphological features and account for up to 25 % of all invasive bre
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL; SERM Chemoprevention of Breast Cancer Overview Group. Cuzick J, et al. Lancet. 2013 May 25;381(9880):1827-34. doi: 10.1016/S0140-6736(13)60140-3. Epub 2013 Apr 30. Lancet. 2013. PMID: 23639488 Free PMC article. Review.
Our primary endpoint was incidence of all breast cancer (including ductal carcinoma in situ) during a 10 year follow-up period. ...Overall, we noted a 38% reduction (hazard ratio [HR] 0·62, 95% CI 0·56-0·69) in breast cancer incidence, and 42 women would need to be …
Our primary endpoint was incidence of all breast cancer (including ductal carcinoma in situ) during a 10 year follow-up period. ...Ov …
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Del Mastro L, Rossi G, Lambertini M, Poggio F, Pronzato P. Del Mastro L, et al. Cancer Treat Rev. 2016 Jan;42:18-23. doi: 10.1016/j.ctrv.2015.11.002. Epub 2015 Nov 21. Cancer Treat Rev. 2016. PMID: 26613834 Review.
Luteinising hormone releasing hormone agonists (LH-RHa) are effective in the treatment of advanced endocrine-sensitive breast cancer in premenopausal patients, but their role in the adjuvant setting has remained controversial for a long time. ...The administration of an ar …
Luteinising hormone releasing hormone agonists (LH-RHa) are effective in the treatment of advanced endocrine-sensitive breast cancer …
617 results
Jump to page
Feedback